BeiGene issues 133M shares internally for re-domiciliation from Cayman to Switzerland

BeOne Medicines Ltd.

Issued 133,000,000 ordinary shares to subsidiary BGNC2 in exchange for 13.7% of BeiGene UK Ltd.
Shares will be deemed treasury shares under Swiss law upon completion of planned re-domiciliation.
Issuance relies on Section 4(a)(2) exemption; shares will be cancelled if re-domiciliation abandoned.
Shares held for benefit of equity award holders under the 2016 Share Option and Incentive Plan.
Swiss issuance stamp tax and withholding tax exemptions apply as shares are created before re-domiciliation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.